CME Grand Rounds for Oncologists, Surgeons
and Ear, Nose and Throat Surgeons

IMER Regional Meeting

Community Oncology Clinical
Debates in Head and Neck Cancer

Click here to request this program for your organization.
Person requesting form:

Contact name/administrative representative (if different from above):
Organization:
Street address:
City:
State:
Zip:
Contact phone:
Contact fax:
Contact E-mail:
Expected number of
medical oncologists:
Expected number of ENTs
Expected number of
surgical oncologists:
Expected number of
general surgeons:
Expected number of
PAs and NPs:
Expected total number
of attendees:
Date and time of requested program (1st choice):
Date and time of requested program (2nd choice):
Date and time of requested program (3rd choice):

Thank you. We value your feedback.

Please allow 2 business days for a response from our office.

Target Audience

This activity has been designed to meet the educational needs of community- and academic-based medical and radiation oncologists and ear, nose, and throat surgeons.

Purpose

To educate oncologists and surgeons on clinical debates arising from recent advances in surgical techniques and multimodality treatments for patients with squamous cell carcinoma of the head and neck (SCCHN).

Program Overview

The treatment of patients with SCCHN is complex and requires a multidisciplinary approach to achieve optimal patient outcomes. Although treatment varies based on tumor size, stage, and patient performance status, the ultimate goals of treatment remain the same: improved survival outcomes, organ function preservation, and improved quality of life. Despite advances in surgical techniques, and the availability of new multimodality treatments, considerable clinical debates remain regarding optimal treatment choices.

This academic- and community-based grand rounds series will focus on the most pivotal debates, including concurrent versus sequential chemoradiotherapy, biologic therapy, surgery, radiation, and the collaborative delivery of quality care. The resolution of these clinical debates will greatly influence the treatment of SCCHN in 2009 and beyond. Thought leader faculty will provide an overview of clinical debates, followed by one or more case studies to stimulate interdisciplinary discussion.

Learning Objectives

Upon completion of this program, participants should be better able to:

  • Describe recent clinical data on patient selection for sequential versus concurrent chemotherapy/chemoradiotherapy, including how to select patients for different pathways of therapy
  • Describe which surgical techniques and systemic regimens are appropriate post-chemoradiotherapy
  • Identify appropriate drug sequencing and the continuation of agents following disease progression
  • Explain recent data on epidermal growth factor receptor inhibitors and their combination with chemoradiotherapy
  • Outline an approach to multidisciplinary collaboration to achieve optimal patient outcomes
  • Describe the role of interdisciplinary functional assessment in optimizing outcomes
Program Agenda
  • Program Overview (5 mins)
  • Overview of Interdisciplinary Debates (25 mins)
    • Case study: For treatment with curative intent, who should receive sequential chemotherapy? Chemoradiotherapy? What prognostic factors can be applied when making treatment decisions?
    • What is the role of epidermal growth factor receptor inhibitors for treatment with curative intent?
    • Should patients with human papillomavirus be treated differently? Should these patients be stratified in future clinical trials?
    • Case study: What is the role of minimally invasive head and neck surgery in the 21st century?
    • Role of neck dissection post chemoradiation: Who, when, and how extensive Interdisciplinary
  • Discussion of Debates and Case Studies (30 mins)

Jointly sponsored by:

IMER
Postgraduate Institute for Medicine

This activity is supported by an independent educational grant from sanofi-aventis U.S.

Select Other Community Oncology Clinical Debates


Additional CME Meetings on This Topic
{date} {city} {speaker}

{icon}
{location}

Faculty

MEDICAL ONCOLOGIST
Marshall R. Posner, MD
(Co-Chairman)
Dana-Farber Cancer Institute


Ezra E.W. Cohen, MD
University of Chicago
Medical Center

Robert I. Haddad, MD
Dana-Farber Cancer Institute

John A. Ridge, MD, PhD, FACS
Fox Chase Cancer Center

SURGICAL ONCOLOGIST
Floyd Christopher Holsinger, MD, FACS
(Co-Chairman)
University of Texas M. D.
Anderson Cancer Center

A. Dimitrios Colevas, MD
 Stanford University
Medical Center

Wayne M. Koch, MD
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

 

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Institute for Medical Education & Research (IMER). PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

 

 

 
```